Skip to main content
NSRX logo

Nasus Pharma Ltd.

NSRXNYSEAMERICANHealthcareDrug Manufacturers - General

$3.18Today:- (-)1Y −59.58%

As of Oct 16, 2026 close

Market cap
$35.04M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.98$9.50
Volume (live)
-
Avg. volume (3M)
18.77K

Nasus Pharma (NSRX) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Nasus Pharma posted a net loss of $5.86M, compared with a net loss of $1.53M a year earlier.

Nasus Pharma Income Statement Analysis

Values in millions USD

Scroll to see more
Nasus Pharma Ltd. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period endingDec 2025Dec 2024Dec 2023Dec 2022
Revenue & Gross Profit
Revenue0.00---
Cost of Revenue0.00---
Gross Profit0.00---
Operating Expenses
Research & Development2.240.340.571.12
Selling, General & Administrative2.670.740.580.93
Operating Expenses4.901.081.152.04
Operating Income-4.90-1.08-1.15-2.04
Other Income/Expense
Interest Income0.00---
Interest Expense0.00-0.030.05-0.02
Other Income/Expense-0.90-0.470.19-0.11
Income
Income Before Tax-5.81-1.55-1.01-2.15
Income Tax Expense0.00---
Net Income-5.86-1.53-1.05-1.71
Net Income - Continuous Operations-5.86-1.55-1.01-2.15
Net Income - Discontinued Operations-0.050.02-0.050.44
EBITDA-4.90-1.08-1.15-2.04
EBIT-4.90-1.08-1.15-2.04
Depreciation & Amortization0.00---
Earnings Per Share
Basic EPS-1.00---
Diluted EPS-1.00---
Basic Shares Outstanding8.017.036.896.89
Diluted Shares Outstanding8.017.037.066.89

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Nasus Pharma Financial Statements

Is Nasus Pharma profitable?

No. Nasus Pharma reported a net loss of $5.86M in fiscal 2025. In fiscal 2024 it lost $1.53M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition